Related Experiment Video
Updated: May 10, 2026
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Does thyroid-stimulating hormone influence the prognosis of patients with endometrial cancer? A multicentre trial
V Seebacher1, G Hofstetter, S Polterauer
1Department of Gynaecology and Gynaecological Oncology, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
Background:
Thyroid function has been suggested to interfere with tumour biology and prognosis in different cancers. The present study was performed to investigate the impact of pre-therapeutic serum thyroid-stimulating hormone (TSH) levels on the prognosis of patients with endometrial cancer.
Methods:
Pre-therapeutic serum TSH was investigated in 199 patients with endometrial cancer. After stratification in TSH risk groups, univariate and multivariable survival analyses were performed.
Results:
Elevated TSH was independently associated with poor disease-specific survival in univariate/multivariable survival analyses (P=0.01 and P=0.03, respectively).
Conclusion:
Thyroid-stimulating hormone may serve as a novel and independent prognostic parameter for disease-specific survival in patients with endometrial cancer.